Speaker Profile
Ph.D., CEO, Galatea Bio
Biography
Dr. Carlos Bustamante is one of the worlds foremost thought leaders in population genetics and genomics and brings immense knowledge and relationships key to the companys success. A leading academic in the field of medical and population genomics, his background includes roles as a Venture Partner at F-Prime Capital, SAB member with Digitalis Ventures, Founder of Arc Bio, advisor to numerous startups, and former Professor of Genetics Biomedical Data Science at Stanford University (now adjunct). Dr. Bustamante was also awarded a MacArthur Fellowship in 2010 for his contributions to population genetics (mining DNA sequence data to address fundamental questions about mechanisms of evolution, origins of human genetic diversity, and patterns of population migration).
Talk
Harnessing Human Diversity to Advance Discovery and Precision Medicine
Ethnic representation bias pervades large-scale genetic datasets, perpetuating disparities in medicine. Galatea Bios global recruitment network targets underserved populations, integrating with biopharma to deliver multimodal data for 10 million patients. By leveraging ancestry-informed analytics and genetic diversity, we aim to eliminate bias, accelerate discoveries, and revolutionize personalized medicine.
Clinical & Research Tools Showcase:
Galatea Bio
Galatea Bio is a biotechnology company committed to driving groundbreaking discoveries in healthcare by pairing genetic diversity with cutting-edge data analytics. Our passion is fueled by a focus on populations historically underrepresented in genetics research.
Session Abstract – PMWC 2025 Silicon Valley
The PMWC 2025 Clinical & Research Tools Showcase will provide a 15-30 minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.
